The role of collagen metabolism in CKD-associated arterial senescence: Underestimated and underappreciated

Nephrology Dialysis Transplantation

Volumn 26, Issue 9, 2011, Pages 2726-2728

  Verbeke, Francis ^a   Van Biesen, Wim ^a   Vanholder, Raymond ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

arterial stiffness; collagen; kidney disease; ventricular hypertrophy

Indexed keywords

CARBOXY TERMINAL TELOPEPTIDE; PLACEBO; PROCOLLAGEN C PROTEINASE; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; SPIRONOLACTONE;

ADD ON THERAPY; ARTERIAL STIFFNESS; ARTICLE; BLOOD VESSEL; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; COLLAGEN DEGRADATION; COLLAGEN METABOLISM; CONGESTIVE HEART FAILURE; HEART LEFT VENTRICLE MASS; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MYOCARDIAL DISEASE; PRIORITY JOURNAL; PROGNOSIS; PULSE WAVE; RENAL REPLACEMENT THERAPY; SENESCENCE; UREMIA;

ARTERIES; BIOLOGICAL MARKERS; COLLAGEN; FEMALE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; KIDNEY FAILURE, CHRONIC; MALE; VASCULAR STIFFNESS;

EID: 80053190427     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfr421     Document Type: Article

References (19)

1. Drueke TB. Arterial intima and media calcification: distinct entities with different pathogenesis or all the same? Clin J Am Soc Nephrol 2008; 3: 1583-1584
2. McCullough PA, Agrawal V, Danielewicz E et al. Accelerated atherosclerotic calcification and Monckeberg's sclerosis: a continuum of advanced vascular pathology in chronic kidney disease. Clin J Am Soc Nephrol 2008; 3: 1585-1598
3. Amann K.Media calcification and intima calcification are distinct entities in chronic kidney disease. Clin J Am Soc Nephrol 2008; 3: 1599-1605
4. Vanholder R, Massy Z, Argiles A et al. Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant 2005; 20: 1048-1056 (Pubitemid 40862092)
5. Weiner DE, Tighiouart H, Elsayed EF et al. The Framingham predictive instrument in chronic kidney disease. J Am Coll Cardiol 2007; 50: 217-224 (Pubitemid 47031564)
6. Sciarretta S, Valenti V, Tocci G et al. Association of renal damage with cardiovascular diseases is independent of individual cardiovascular risk profile in hypertension: data from the Italy-Developing Education and awareness on MicroAlbuminuria in patients with hypertensive Disease study. J Hypertens 2010; 28: 251-258
7. Aronson D. Cross-linking of glycated collagen in the pathogenesis of arterial and myocardial stiffening of aging and diabetes. J Hypertens 2003; 21: 3-12 (Pubitemid 36143498)
8. Vaitkevicius PV, Lane M, Spurgeon H et al. A cross-link breaker has sustained effects on arterial and ventricular properties in older rhesus monkeys. Proc Natl Acad Sci USA 2001; 98: 1171-1175 (Pubitemid 32121205)
9. Cantini C, Kieffer P, Corman B et al. Aminoguanidine and aortic wall mechanics, structure, and composition in aged rats. Hypertension 2001; 38: 943-948 (Pubitemid 34258698)
10. Wolffenbuttel BH, Boulanger CM, Crijns FR et al. Breakers of advanced glycation end products restore large artery properties in experimental diabetes. Proc Natl Acad Sci USA 1998; 95: 4630-4634
11. Kass DA, Shapiro EP, Kawaguchi M et al. Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation 2001; 104: 1464-1470 (Pubitemid 32917336)
12. Chen J, Brodsky SV, Goligorsky DM et al. Glycated collagen I induces premature senescence-like phenotypic changes in endothelial cells. Circ Res 2002; 90: 1290-1298 (Pubitemid 34787411)
13. Dellegrottaglie S, Sands RL, Gillespie BW et al. Association between markers of collagen turnover, arterial stiffness and left ventricular hypertrophy in chronic kidney disease (CKD): the Renal Research Institute (RRI)-CKD Study. Nephrol Dial Transplant 2011; doi: 10.1093/ndt/gfr186
14. Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-717 (Pubitemid 29407370)
15. Zannad F, Alla F, Dousset B et al. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation 2000; 102: 2700-2706
16. Ho CY, Lopez B, Coelho-Filho OR et al. Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy. N Engl J Med 2010; 363: 552-563
17. Marchais SJ, Guerin AP, Pannier BM et al. Wave reflections and cardiac hypertrophy in chronic uremia. Influence of body size. Hypertension 1993; 22: 876-883 (Pubitemid 23358096)
18. Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol 2010; 55: 1318-1327
19. Verbeke F, Van BW, Honkanen E et al. Prognostic value of aortic stiffness and calcification for cardiovascular events and mortality in dialysis patients: outcome of the calcification outcome in renal disease (CORD) study. Clin J Am Soc Nephrol 2011; 6: 153-159